Elevar Therapeutics Receives FDA Conditional Acceptance For Lyrfigtu Brand Name

Elevar Therapeutics said the FDA conditionally accepted LYRFIGTU as the proposed brand name for lirafugratinib. The drug remains under FDA Priority Review, making the naming decision a positive regulatory-readiness milestone but not an approval decision.